BioSpace News Archive

Quotient Limited (NASDAQ:QTNT), a commercial-stage diagnostics company, today announced that financial results for its fiscal third quarter ended December 31, 2020 will be released before market open on Monday, February 1, 2021.

Rhythm Pharmaceuticals, Inc. (Nasdaq:RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced that it plans to host a virtual event on Tuesday, January 26, 2021 from 8 to 10 a.m. ET to provide an update on its ongoing exploratory Phase 2 Basket Study and genetic sequencing efforts.

Algernon Pharmaceuticals Inc. (CSE: AGN) (FRANKFURT: AGW) (OTCQB: AGNPF) (the “Company” or “Algernon”) a clinical stage pharmaceutical development company, is pleased to announce that the external Data and Safety Monitoring Board (“DSMB”) has completed its latest review of the Phase 2b part of the Company’s Phase 2b/3 human study of NP-120 (Ifenprodil) for the treatment of COVID-19, and has provided approval for the Company to continue on with the Phase 3 part of the study.

Healthcare Industry Veteran to Lead Blink Science Efforts in Developing the World’s First Instant COVID POC Diagnostic Testing Device and Launching a Comprehensive Electronic Medical Passport

AgBiome, a leader in developing innovative products from the Earth’s microbial communities, announced Dr. Marijn Dekkers as the company’s Chairman, effective January 1, 2021.

A senior secured term loan will support the further development of VERO Biotech’s GENOSYL® Delivery System, a proprietary tankless and portable delivery system for the administration of GENOSYL® (nitric oxide) gas, for inhalation

Sumitomo Dainippon Pharma Oncology, Inc., a developer of novel cancer therapeutics, today announced that the first patient has been dosed in a Phase 1/2 study evaluating the investigational agent TP-0184, an activin receptor-like kinase 2 (ALK2) and ALK5 inhibitor, for the treatment of anemia in adult patients with low or intermediate risk myelodysplastic syndromes (MDS).

A new study in Mayo Clinic Proceedings entitled “Aseptic Stethoscope Barriers Prevent C. difficile Transmission In Vitro"2 finds that aseptic disk covers from AseptiScope, available now commercially in the company’s flagship product, The DiskCover System™, completely blocked the growth of C. difficile on stethoscope diaphragms.

Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, today announced it has entered into a definitive agreement to acquire Mesa Biotech, Inc., a privately held molecular diagnostic company, for approximately $450 million in cash

Ace Vision Group, Inc, an emerging ophthalmic laser device company focused on bringing innovative touchless Eye Laser Therapy to patients suffering from age related vision loss, announced that it closed a Series A preferred stock round totaling $13.3M, which is $3.3M oversubscribed.